22.03.2021

ELAA Technology is accepted onto Bruntwood Scitech's Alderley Park Oncology Development Programme

ELAA Technology is honored to be one of the 35 startups selected out of 86 highly competent applicants for Alderley Park Oncology Development Programme with its lead digital health product for early lung cancer diagnosis : PRECIMON.

The Alderley Park Oncology Development Programme is a national programme designed to develop and progress start-up oncology projects. Funded by Innovate UK and Cancer Research UK, the programme brings together a unique collaboration of global pharmaceutical and healthcare companies, research institutions and public bodies to identify and progress exciting oncology innovations that will improve the diagnosis and treatment of cancer. Its goal is to bring forward viable oncology projects much more quickly in order to significantly increase their likelihood of commercial success, and ultimately, patient benefit.

A collaboration of AstraZeneca, Johnson & Johnson Innovation, GlaxoSmithKline, Roche, The Christie NHS Foundation Trust, Medicines Discovery Catapult and the Manchester Cancer Research Centre will support researchers and start-ups aiming to develop their early-stage innovations. As delivery partner for the programme, Medicines Discovery Catapult, a national hub for research and development in drug discovery, will work closely with the selected participating researchers and start-ups, to help them develop fully validated, timed, costed, project plans with delivery partners in place, vastly improving their likelihood of attracting future investment.

"We have been developing our lead product candidate PRECIMON which is pure digital medical navigation technology for lung cancer early diagnosis and even during the Covid-19 pandemic we could be able to receive our CE mark as a class-IIa medical device. We strongly believe that Alderley Park's Oncology Development Programme will enable us to demonstrate the capabilities of PRECIMON and help us sharpen our skills to move forward on our goal to create an AI driven digital health diagnostics company. We are now aiming to launch a health technology assesment study in order to strengthen our position and create enough data for analyzing the burden we can remove on healthcare systems after this pandemic" commented Dr.Tunc Lacin,Chief Scientific Officer of ELAA Technology and the thoracic surgeon invented this platform technology out of his immediate need.

"We had been awarded as the 1st seat in the Alderley Park Accelerator Programme in 2020 thanks to our hard work and our mentors' efforts. This time we are thrilled to be selected onto participate this breakthru programme and cannot wait to see the results on how this programme may help us to shape ELAA Technology and our lead product candidate PRECIMON in a better way. We believe after Covid-19 pandemic, digital health and early diagnosis will be crucial for keeping up the sustainability in healthcare system in nations and we are proud to offer the community a digital health medical device which is a great candidate for decreasing healthcare expenditures via lung cancer early diagnosis. We are grateful to Alderley Park Oncology Development Programme Executive Committee for offering us a position here, this is a long run and we will work harder to deserve" commented Arda Karaduman, CEO of ELAA Technology

 

 

About ELAA Technology :

ELAA Technology is a digital health company focusing on cancer early diagnosis . ELAA Technology’s patent pending Pure Digital Medical Navigation Platform has been the basis for development of new products for cancer early diagnosis market starting with its first product PRECIMON designed for lung cancer.